Medindia

X

ContraVir to Present at Upcoming Investor and Industry Conferences

Tuesday, September 6, 2016 Corporate News J E 4
Advertisement

EDISON, N.J., Sept. 6, 2016 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced that it will present at two upcoming conferences in September 2016.  CEO James Sapirstein will provide an overview of the company's business during live presentations, and will be available to participate in one-on-one meetings with investors who are registered to attend the events.

Conference Details:

Event: Rodman & Renshaw 18th Annual Global Investment ConferenceDate: September 12, 2016Time: 11:15am – 11:40am (Eastern Time) Location: New York Palace Hotel; New York

Event: BioPharm AmericaDate: September 15, 2016Time: 11:30am (Eastern Time)Location: Boston Marriot Copley Place; Boston, MA

About ContraVir PharmaceuticalsContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action: CMX157, a highly potent analog of the successful antiviral drug tenofovir currently in Phase 2a, which has demonstrated the potential for low, once a day dosing compared to Viread® and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV.  ContraVir is also developing FV-100, an orally available nucleoside analogue prodrug for the treatment of herpes zoster, or shingles, in a Phase 3 clinical trial.  In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study. For more information visit www.contravir.com.

Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on ContraVir's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. ContraVir does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in ContraVir's Form 10-K for the year ended June 30, 2015 and other periodic reports filed with the Securities and Exchange Commission.

For further information, please contact:

Sharen PyatetskayaDirector of Investor Relationssp@contravir.com; (732) 902-4028

Tiberend Strategic Advisors, Inc.Joshua Drumm, Ph.D. (investors)jdrumm@tiberend.com; (212) 375-2664

Claire Lacagnina (media)clacagnina@tiberend.com; (212) 375-2686

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/contravir-to-present-at-upcoming-investor-and-industry-conferences-300322264.html

SOURCE ContraVir Pharmaceuticals, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
RXi Pharmaceuticals to Present at the 9th Annual B...
S
Nasogastric Tube Market 2016 Global Analysis and 2...